Edwards Lifesciences Corporation (NYSE:EW) will be discussing 3Q20 financial results with the investment community.on 21st October 2020 at 5:00 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.edwards.com
Earnings Expectation
Edwards Lifesciences Corporation is reporting third quarter earnings results on Wednesday 21st October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.44 per share from $ 1079.78 million in revenue. For the full year, analysts predict revenues of $ 4382.60 million, while looking forward to income of $ 1.84 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 1,000.00 million ~ $ 1,200.00 million
Full Year 2020 topline are forecasted in a range of$ 4,000.00 million ~ $ 4,500.00 million, where as bottomline are predicted in a range of $ 1.75 ~ $ 1.95 per share
Click Here For More Historical Outlooks Of Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery.
